Related Experiment Video

Updated: Mar 1, 2026

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

1.1K

New antimicrobial strategies in cystic fibrosis

Mireille van Westreenen1, Harm A W M Tiddens

  • 1Department of Medical Microbiology & Infectious Diseases, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands. m.vanwestreenen@erasmusmc.nl

Paediatric Drugs
|October 30, 2010
PubMed

Insights

New inhaled antibiotics and advanced delivery systems offer hope for cystic fibrosis (CF) patients battling resistant lung infections. These emerging strategies aim to improve treatment efficacy and reduce patient burden.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Increasing antibiotic resistance and emerging pathogens in cystic fibrosis (CF) patients necessitate novel treatment strategies.
  • Pseudomonas aeruginosa is a primary pathogen in CF lung disease, but other bacteria also contribute to pathogenesis.
  • Current treatment options for CF pulmonary infections are limited, highlighting an urgent need for expansion.

Purpose of the Study:

  • To review recent advancements in antimicrobial strategies for cystic fibrosis (CF) lung infections.
  • To highlight new drug formulations, delivery routes, and antibiotic analogs for CF treatment.
  • To assess the clinical development status of novel antimicrobial approaches for CF.

Main Methods:

  • Review of current literature on antimicrobial strategies for CF.
  • Focus on new formulations, delivery systems, and antibiotic analogs.
  • Analysis of preclinical and clinical development phases of novel CF treatments.

Main Results:

  • Development of new inhaled antibiotics (aztreonam, levofloxacin, fosfomycin) is in the clinical phase.
  • Novel delivery systems, including dry powder inhalation and liposomes, are advancing for current antibiotics.
  • Most new antibiotic-like drugs are in preclinical development, with few expected to reach the market.

Conclusions:

  • Emerging inhaled antibiotics and advanced delivery systems show promise for improving CF treatment.
  • These innovations have the potential to enhance treatment effectiveness and decrease the burden on CF patients.
  • Continued research and development are crucial for addressing the evolving challenges of CF lung infections.

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.9K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.2K

Related Concept Videos

Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
781
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
590
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
953
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Surface Membrane Barriers01:18

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
3.1K